© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cardiologists spent decades hoping for a new class of treatments to tackle heart failure, as common drugs gave only short-term relief or left major risks unaddressed. Scientists explored neprilysin as a target back in the 1990s, understanding how that enzyme plays a role in breaking down natriuretic peptides. A team at Novartis pushed those early ideas into the clinic, gradually refining several molecules until sacubitril emerged as the frontrunner, particularly when paired with valsartan. The landmark PARADIGM-HF trial showed that this combo could cut down the risk of cardiovascular death and hospitalizations, and so in 2015, regulators gave the green light. This marked a concrete shift for millions of patients—and a rare win for innovation in chronic disease management.
Found in the clinic as half of the dual-acting agent in Entresto, sacubitril sodium is a neprilysin inhibitor. Doctors prescribe it for people suffering from heart failure with reduced ejection fraction. Sacubitril on its own never made sense for treatment—its real strength comes from working alongside valsartan, a familiar angiotensin receptor blocker. By combining these, the product tackles two pathways at once, raising certain peptide levels and limiting the negative effects of RAAS activity.
Sacubitril sodium appears as a white to almost white powder, with odorless or faintly aromatic qualities. Its molecular formula is C24H29NO5Na, weighing in at about 434.48 g/mol. It dissolves well in water and methanol and poorly in non-polar solvents, which influences both how pharmacists formulate tablets and how generic manufacturers process the compound. It decomposes above 250 degrees Celsius. These practical qualities matter to anyone trying to synthesize, store, or prepare the drug for patient use.
Products containing sacubitril sodium arrive with strict identification and purity standards. Regulators set limits for impurities like valsartan-related substances, residual solvents, and water content, often requiring less than 0.5% for any individual impurity and below 2% total. Tablets come labeled with mg-equivalent content (often 24 mg, 49 mg, or 97 mg per dose). Drug leaflets warn users not to take the medication with ACE inhibitors and stress the importance of monitoring for kidney function, blood pressure, and signs of angioedema. Lots must meet batch-release specifications before reaching clinics, including clarity, dissolution, and particle size checks.
Labs produce sacubitril by linking an arylalkyl acid with a biphenyl derivative through amide bond formation. Chemists protect and deprotect functional groups at several stages, isolating intermediates via crystallization or chromatography. Pure sacubitril then reacts with sodium hydroxide for sodium salt formation. Batch production brings its own headaches—using powerful solvents, handling sensitive reagents, and requiring careful pH adjustment to guarantee yield and purity. Industrial plants automate much of the process, but hands-on monitoring ensures no surprise by-products slip through.
Sacubitril’s major action in the body actually starts after ingestion. Esterases in the liver convert it into sacubitrilat, the active metabolite that blocks neprilysin. The parent molecule remains stable in the solid state, but under stress from heat or moisture, sacubitril sodium can hydrolyze or lose integrity. Chemical modifications to tweak the side chain or core structure rarely produce much better activity or safety profiles, so pharmaceutical R&D still focuses on cutting process costs or improving tablet stability rather than radical redesign of the molecule.
Few outside the industry call sacubitril sodium by its IUPAC name, but chemists might label it as LCZ696-NEP or AHU-377 sodium salt. The finished drug combination is known in pharmacies as Entresto, but generics pending approval parade a mix of variations on “sacubitril/valsartan” or “sacubitril sodium salt” plus a manufacturer brand. It’s not unusual to find this compound cited as simply “sacubitril sodium” in active pharmaceutical ingredient (API) catalogs.
Sacubitril sodium lands on the list of substances where staff need gloves, goggles, and local exhaust ventilation in manufacturing suites. Chronic exposure risks stay under review, pushing facilities to keep dust levels low and avoid skin or eye contact. Disposal of laboratory waste follows hazardous substance rules, mandating incineration for large amounts and dilution for smaller spills. Packaging lines include metal detectors and humidity controls to prevent tablet recalls. Any deviation in quality triggers an immediate review because the window for safe, effective therapy is tight.
Doctors now view sacubitril sodium, always paired with valsartan, as the gold standard for cutting down cardiovascular mortality and days spent in hospital among people wrestling with heart failure with reduced ejection fraction. Its use is expanding—guidelines recommend it not just after failure of older drugs but much earlier in disease progression. Some researchers are curious about whether it might help patients with preserved ejection fraction or specific kidney problems, but results have been mixed. While off-label experimentation continues worldwide, regulators stick to evidence from major clinical trials and post-marketing studies.
Academic centers devote resources to teasing out exactly how neprilysin inhibition improves clinical outcomes. Some focus on understanding how sacubitril sodium tweaks neurohormones and reduces fibrosis in the heart and blood vessels. Biotech startups eye process improvements—trying greener solvents or continuous flow syntheses to drop production costs or improve environmental footprints. Drug designers tinker with related compounds in search of agents that offer similar survival benefits for other chronic diseases, like diabetic nephropathy or resistant hypertension. These efforts chase both increased safety and fresh intellectual property.
After studying thousands of patients, scientists determined that sacubitril sodium, in combination with valsartan, mainly causes risks tied to excessive blood pressure drops, kidney issues, and higher potassium. Angioedema proved rare but remains one of the most serious side effects, shared with other drugs hitting the same pathways. In rodents and dogs, high doses led to weight changes and liver enzyme bumps, but these doses were much higher than those used clinically. Reproductive and cancer studies did not reveal strong red flags, though post-market surveillance keeps tracking odd reactions. For the typical patient, toxicity risks can be managed with careful dosing and regular blood checks.
As blockbuster drugs go generic, sacubitril sodium seems destined for broader access and lower prices. Some health systems support head-to-head studies against older antihypertensives, hoping to justify switching even more patients to this therapy. Scientists haven’t given up on exploring new indications—they push for trials in conditions like chronic kidney disease and difficult-to-treat hypertension. Improvements in formulation technology, like orodispersible tablets or fixed-dose combinations with other agents, may help more patients take their medicines reliably. Drug safety teams monitor rare side effects and drug-drug interactions, keeping information flowing to prescribers. The years ahead could bring wider use and maybe new chemical cousins for problems that today still seem out of reach.
Sacubitril sodium plays a leading role in treating heart failure with reduced ejection fraction. Heart failure drags down quality of life for millions, leaving people with constant fatigue, shortness of breath, and limited activity. I’ve watched family members struggle with the basics—climbing stairs or even walking across a room—when their hearts couldn’t keep up. Newer medicines like sacubitril sodium have helped reshape expectations for patients facing this condition.
This medication doesn’t work on its own. It gets combined with another ingredient called valsartan to form a treatment known as sacubitril/valsartan, or by its brand name, Entresto. Doctors didn’t back this drug out of thin air; the science behind it is strong. Sacubitril blocks an enzyme that would normally break down certain proteins, which help blood vessels relax and remove excess salt from the body. Combined with valsartan—an angiotensin receptor blocker—it lightens the strain on the heart. Clinical studies show real changes: patients on this combination stay out of the hospital longer and live longer.
The PARADIGM-HF study, which followed over 8,000 people, changed how doctors saw heart failure management. People treated with sacubitril/valsartan had fewer cardiovascular deaths and hospitalizations than those on the old standard, enalapril. It’s rare to see a clear improvement like this in medicine. I’ve seen friends recover lost energy and pick up activities they’d put aside for years after starting this treatment.
One big hurdle for patients is the cost. Insurance plans don’t always make it easy to get the medications specialists recommend. Sacubitril sodium isn’t as cheap as some older drugs, so some people still face tough decisions about their care. High prices, insurance red tape, or lack of awareness block people from getting the full benefits. Even though the FDA approved sacubitril/valsartan in 2015 for heart failure, I meet people who’ve never heard about it—or don’t know they could qualify.
Doctors, pharmacists, and insurers should work together to close these gaps. More education, patient support programs, and policy changes could clear the path. Real lives hang in the balance when access to life-improving care remains out of reach. Community clinics and health fairs can step up too by spreading awareness about advances like sacubitril/valsartan.
Sacubitril sodium isn’t a miracle pill, but for many, it’s been a vital addition to the fight against heart failure. Anyone dealing with worsening symptoms should have a real conversation with their doctor about modern options. Our healthcare systems can do more to help patients find these therapies sooner, rather than relying on outdated routines.
Medical progress only matters when it reaches the people who need it most. Sacubitril sodium has already shifted the landscape for heart failure. The next step is making sure everyone who stands to benefit gets informed and supported. That’s the real test of any medical advance.
People dealing with chronic heart failure face daily hurdles. Shortness of breath, weakness after climbing stairs, or waking up tired can point to a bigger problem: the heart can’t keep up with the body’s demands. Doctors once favored drugs such as ACE inhibitors and beta-blockers when managing this. Sacubitril sodium changed the approach.
Sacubitril sodium doesn’t work alone. It often comes paired with valsartan in a combination pill called Entresto. Valsartan blocks a hormone signal that tightens blood vessels, letting blood flow more easily. Sacubitril offers something extra. Instead of focusing on the usual pathways, it targets enzymes that break down helpful natural hormones called natriuretic peptides.
Our bodies release natriuretic peptides when the heart experiences stress or stretches. These peptides relax blood vessels, flush out excess salt through urine, and lower blood pressure. All these effects lighten the heart’s load. Normally, an enzyme called neprilysin breaks down these peptides, limiting their benefits. That’s where sacubitril steps in. By blocking neprilysin, it allows more of these helpful hormones to circulate. With more of them around, the body flushes out excess fluid and the heart works less strenuously.
The switch to the sacubitril/valsartan combo didn’t happen by accident. Leading clinical trials, like the massive PARADIGM-HF study, offered real proof. People taking this combo lived longer, avoided more hospital visits, and felt better overall compared to those using traditional ACE inhibitors. The difference in patient quality of life drew attention from both everyday cardiology clinics and academic research.
No drug solves everything overnight. Sacubitril sodium brings hope but also poses challenges. Kidney function and blood potassium levels can shift with this medication, so doctors check lab results and adjust doses often. People with a history of angioedema—swelling in the face or throat—require alternatives, because blocking neprilysin raises risk in those prone to this reaction.
A practical hurdle I’ve seen in real practice involves cost. Name-brand therapies like sacubitril/valsartan can carry a hefty price, even with insurance. People sometimes hesitate to fill prescriptions, knowing the price tag. A solution lies in insurance advocacy—when clinic nurses and pharmacists help patients navigate assistance programs, folks stay on track with their treatments.
Heart failure feels like an uphill battle for millions. I’ve watched family members struggle to catch their breath after mild effort, then rebound after treatment adjustments. Sacubitril sodium, with more thoughtful targeting of the body’s own hormone systems, opens new possibilities. While many drug innovations get hyped without real change, this one delivers clear benefits to patients seen both in the research lab and at the bedside.
Medications often bring hope for people living with heart failure. Sacubitril sodium, found together with valsartan in a popular heart pill, promises better days for many who struggle with shortness of breath, fatigue, and swelling. Still, no medication comes free from side effects. Coming from a family touched by heart failure, and through years following health research, I’ve learned that knowing what could go wrong sometimes matters just as much as knowing what might go right. Real-world stories echo this—catching trouble early can be the difference between peace of mind and a hospital visit.
The most talked-about issue with sacubitril sodium remains the drop in blood pressure. Dizziness, lightheadedness, and even fainting can show up in daily life, not just right after that first dose. People might think they’re just having a busy day and stand up too quickly, only to feel their world spin. Extra caution helps, especially for older adults or those already juggling lots of medications.
Kidney health sits close behind as a concern. The kidneys work overtime in heart failure, and certain drugs can put more strain on those hardworking organs. Regular bloodwork keeps small changes from spiraling out of control. Tiredness or appetite loss should never be brushed off. When my grandfather noticed swelling in his feet, labs showed his kidneys weren’t happy. His doctor tweaked his pills, caught the problem, and turned things around.
Sacubitril sodium impacts levels of a mineral called potassium. High potassium (hyperkalemia) can build silently, then suddenly trigger muscle weakness or heart rhythm problems. One friend, new to this pill, learned to pass on the salt substitutes, bananas, and orange juice. A simple blood test told her doctor when to dial back her dose.
Some folks complain of a nagging cough or tightness in the throat. It rarely turns deadly, but it can make falling asleep rough. More troubling, swelling of the lips, tongue, or face signals a rare but dangerous reaction called angioedema. Anyone who notices their throat closing up needs emergency care. For those of African descent, the risk climbs a little higher. Family history and past reactions to similar medicines deserve an honest conversation with a doctor.
Nausea, belly pain, and diarrhea don’t sound extreme, yet anyone with heart issues can get run down fast. Dehydration saps strength and puts the heart under extra stress. I’ve heard patients complain about feeling wiped out after just a week on a new medicine. Staying alert to these small flags and reporting them helps find the right pill or a safer dose.
Living with side effects shouldn’t mean giving up hope or stopping medication alone. Checking blood pressure at home, reading up on warning signs, and keeping in touch with a trusted healthcare provider all go a long way. Many doctors adjust doses, switch brands, or add other medicines to soften side effects. Real improvement comes from teamwork—patients listening to their bodies, families watching for changes, and clinicians open to hearing those lived experiences. Medications like sacubitril sodium can change lives, but only when people know what to watch for and how to react.
Heart failure brings real stress. Shortness of breath, swelling in the legs, and fatigue often disrupt daily living. Medications can make a difference, and Sacubitril Sodium represents a new way to control problems for people with reduced ejection fraction heart failure. This drug usually appears combined with Valsartan—together called an ARNI (angiotensin receptor neprilysin inhibitor). The right approach starts with knowing what this medicine does and how to use it safely.
Doctors like to see patients take Sacubitril Sodium at about the same time each day. Our bodies settle into habits, and this makes missing doses less likely. Sacubitril Sodium doesn’t hide in a long list of medications—stay steady, morning and night, about 12 hours apart. Some people set reminders on their phone or keep their pills next to the toothbrush. Fewer skipped doses mean better control over blood pressure and less strain on the heart.
Meals don’t change how Sacubitril Sodium works. People can take it with food or on an empty stomach, based on what feels best. For those who get nausea from medicines, eating a small snack before swallowing a pill can settle the stomach. Every body reacts differently, so it’s worth paying attention to side effects and bringing up concerns during the next doctor’s visit.
Not everyone starts at the same dose. Doctors study kidney function, blood pressure, and past medication reactions before picking how much to give. An early swallow of too much can make people feel dizzy or lightheaded. Cutting back salt in the diet and watching out for dehydration matters—some drugs for heart failure pull extra water off the body and Sacubitril Sodium can add to that effect.
Forgetting a dose happens in busy lives. If the next scheduled time is close, patients should usually wait and just stick to the plan. Doubling up doesn't speed recovery but can trigger extra side effects like low blood pressure or fainting. Most nurses, including the ones I’ve worked with, stress that a single missed dose rarely causes harm—as long as it does not become a pattern. Open talks with health providers go a long way toward building an approach that fits real life.
Common complaints—dizziness, cough, or a bit of swelling—deserve attention, though some fade with time. Serious issues like severe swelling, breathing changes, or dark urine need a direct call to the doctor. A small group can develop angioedema, or rapid swelling of the face, which requires emergency care. Side effects cause more fear in theory than practice, but education brings peace of mind to both patients and family.
Anybody prescribed Sacubitril Sodium should expect strong advice from a doctor or pharmacist. Writing down instructions and asking about each medication keeps everything clear. Patients at my clinic often read the patient leaflet for ideas on what fits into daily habits, but real questions pop up after a few weeks on the medication.
Sacubitril Sodium has changed the outlook for many struggling with heart failure. Clear steps—routine, listening to your body, and working closely with your provider—help unlock its full potential and support a more active daily life.
Working in a hospital pharmacy, I've seen the impact of new heart medications like sacubitril sodium up close. Approved for heart failure, it’s now written on prescriptions everywhere. Sacubitril’s combination with valsartan—often sold as Entresto—promises better symptom control and even longer lives for people dealing with weak hearts. Since heart failure hits so many homes, no one can overlook the value of a tool that helps keep people out of the hospital.
Most folks on sacubitril already take a bagful of daily prescriptions. That’s where things can get tricky. Mixing up the wrong medicines risks everything from mild discomfort to silent kidney damage. A big concern comes from ACE inhibitors like lisinopril, captopril, or enalapril. Combining sacubitril with any of these can bring life-threatening swelling of the face and throat—a reaction called angioedema. The FDA urges patients and doctors to leave a gap of at least 36 hours between stopping an ACE inhibitor and starting sacubitril.
People living with heart failure often juggle spironolactone or eplerenone, both part of the mineralocorticoid receptor antagonist group. Mixing these water pills with sacubitril and valsartan can raise potassium levels dangerously high. Noticing muscle weakness, irregular heartbeats, or feeling sickly demands attention. Potassium checks by blood draw and medication adjustments help head off a crisis before it puts someone in the ER.
Many who need sacubitril also rely on water pills like furosemide or torsemide to keep fluid from building up. Together, these drugs can work well, but they sometimes drop blood pressure or tweak kidney lab results. This might mean dizziness, fainting, or cramps. Blood chemistry reveals the truth: too much drop means the dose needs to shift or the drug needs to change completely.
For those on blood pressure medications like beta blockers or calcium channel blockers, sacubitril can push some patients into low blood pressure territory. I’ve seen athletes end up flat on the bench because they felt weak. People need to speak up if they feel dizzy or exhausted, especially after medication adjustments.
Some diabetes drugs like aliskiren or sitagliptin raise more alarms. Sacubitril mixed with these increases risks of kidney problems or swelling. Diabetics already play a high-stakes game with circulation, and compounding risks isn’t smart.
Doctors and pharmacists track each medication and watch for new symptoms—this protects heart failure patients. Every prescription check matters. Electronic drug alerts in pharmacies often catch dangers before they reach the bottle. Patients also play a role: keeping a meds list handy, bringing it to appointments, and mentioning any weird symptoms helps the care team spot trouble early.
Educational handouts and honest conversations about what to expect from each medication—both good and bad—go a long way. Everyone involved has a duty to report something that just doesn’t seem right. Early action and good communication keep patients safer and medications working the way they should.
| Names | |
| Preferred IUPAC name | sodium; (2S,4R)-5-(4-biphenylyl)-4-((3-carboxypropanoyl)amino)-2-methylpentanoate |
| Other names |
AHU-377 Sodium sacubitril N-[[(1S,3R)-1-carbamoyl-3-methylbutyl]oxy]-3-(2,2-dimethylpropionyl)-2,3-dihydro-1H-isoindole-1-carboxamide sodium salt |
| Pronunciation | /saːˈkjuːbɪtrɪl ˈsəʊdiəm/ |
| Identifiers | |
| CAS Number | 1369773-39-6 |
| Beilstein Reference | 3624763 |
| ChEBI | CHEBI:134876 |
| ChEMBL | CHEMBL3301617 |
| ChemSpider | 157375 |
| DrugBank | DB11703 |
| ECHA InfoCard | 100.240.344 |
| EC Number | 877399-52-5 |
| Gmelin Reference | 1233281 |
| KEGG | D10641 |
| MeSH | D000068877 |
| PubChem CID | 11450041 |
| RTECS number | VI5457120 |
| UNII | 71X2Q02H74 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C24H25NaO8 |
| Molar mass | 957.99 g/mol |
| Appearance | White or almost white powder |
| Odor | Odorless |
| Density | Density: 1.4±0.1 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.8 |
| Acidity (pKa) | pKa = 4.53 |
| Basicity (pKb) | 10.6 |
| Magnetic susceptibility (χ) | -61.0×10^-6 cm^3/mol |
| Refractive index (nD) | 1.62 |
| Dipole moment | 7.5 ± 1.0 D |
| Pharmacology | |
| ATC code | C09DX04 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | H315, H319, H335 |
| Signal word | Warning |
| Hazard statements | Hazard statements: H315, H319, H335 |
| Precautionary statements | Precautionary statements: Store protected from moisture, at a temperature not exceeding 30°C. Keep out of reach of children. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 356.3°C |
| Autoignition temperature | 400 °C |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | > 2000 mg/kg (rat, oral) |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 50 mg |
| IDLH (Immediate danger) | Not listed. |
| Related compounds | |
| Related compounds |
Sacubitril Valsartan Sacubitril/valsartan AHU-377 Entresto Omapatrilat |
